$EUDA
EUDA Health Holdings Ltd Stock $euda

$euda Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-K Financial Statement

#000149315222024263 Filed on August 29, 2022

Income Statement

Concept	2022 Q3	2022	2021 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue		$6.487M
YoY Change		2.96%
Gross Profit		$3.354M
YoY Change		-20.97%
Gross Profit Margin
Selling, General & Admin		$9.056M
YoY Change		69.48%
% of Gross Profit		269.99%
Research & Development		$17.21K
YoY Change		-86.69%
% of Gross Profit		0.51%
Depreciation & Amortization		$23.35K
YoY Change		-32.37%
% of Gross Profit		0.7%
Operating Expenses	$1.233M	$1.986M	$8.380K
YoY Change	14612.29%	23596.3%
Operating Profit		-$1.986M
YoY Change		61.68%
Interest Expense	$213.5K	$222.9K
YoY Change		1.32%
% of Operating Profit
Other Income/Expense, Net		$222.9K
YoY Change		-89.76%
Pretax Income	-$1.019M	-$1.763M	-$8.380K
YoY Change	12064.32%	20936.28%
Income Tax		$17.42K
% Of Pretax Income
Net Earnings	-$1.019M	-$1.763M	-$8.380K
YoY Change	12064.32%	20936.25%
Net Earnings / Revenue
Basic Earnings Per Share		-$2.07
Diluted Earnings Per Share	-$91.80K	-$213.9K	-$4.469K
COMMON SHARES
Basic Shares Outstanding	11.07M shares	12.03M shares
Diluted Shares Outstanding		12.03M shares

Balance Sheet

Concept	2022 Q3	2022	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$193.6K	$193.6K
YoY Change		1.87%
Cash & Equivalents	$193.5K
Short-Term Investments
Other Short-Term Assets	$86.58M	$86.58M
YoY Change		20086.06%
Inventory
Prepaid Expenses	$109.1K		$181.0K
Receivables		$1.852M
Other Receivables		$22.17M
Total Short-Term Assets	$86.78M	$86.78M	$428.9K
YoY Change	20131.19%	20131.19%
LONG-TERM ASSETS
Property, Plant & Equipment		$124.5K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$478.1K
YoY Change
Total Long-Term Assets	$0.00	$0.00	$0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$86.78M	$86.78M	$428.9K
Total Long-Term Assets	$0.00	$0.00	$0.00
Total Assets	$86.78M	$86.78M	$428.9K
YoY Change	20131.19%	20131.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$1.635M
YoY Change
Accrued Expenses	$824.4K	$824.4K	$3.640K
YoY Change	22548.63%	22548.63%
Deferred Revenue
YoY Change
Short-Term Debt	$800.0K	$800.0K
YoY Change
Long-Term Debt Due		$7.190K
YoY Change
Total Short-Term Liabilities	$4.730M	$4.730M
YoY Change		1083.1%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities		$0.00
YoY Change
Total Long-Term Liabilities	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.730M	$4.730M
Total Long-Term Liabilities	$0.00	$0.00
Total Liabilities	$4.730M	$4.730M	$399.8K
YoY Change	1083.11%	1083.1%
SHAREHOLDERS EQUITY
Retained Earnings	-$3.724M		-$8.377K
YoY Change	44349.68%
Common Stock	$0.00		$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$3.724M	$82.05M	$29.12K
YoY Change
Total Liabilities & Shareholders Equity	$86.78M	$86.78M	$428.9K
YoY Change	20131.19%	20131.19%

Cashflow Statement

Concept	2022 Q3	2022	2021 Q3
OPERATING ACTIVITIES
Net Income	-$1.019M	-$1.763M	-$8.380K
YoY Change	12064.32%	20936.25%
Depreciation, Depletion And Amortization		$23.35K
YoY Change		-32.37%
Cash From Operating Activities	-$353.3K	-$1.006M
YoY Change
INVESTING ACTIVITIES
Capital Expenditures		$18.14K
YoY Change		826.78%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$86.25M
YoY Change		0.0%
Cash From Investing Activities	$0.00	-$86.25M
YoY Change		24115.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	$87.45M
YoY Change		-52038.12%
NET CHANGE
Cash From Operating Activities	-353.3K	-$1.006M
Cash From Investing Activities	0.000	-$86.25M
Cash From Financing Activities	0.000	$87.45M
Net Change In Cash	-353.3K	$193.5K
YoY Change
FREE CASH FLOW
Cash From Operating Activities	-$353.3K	-$1.006M
Capital Expenditures		$18.14K
Free Cash Flow		-$1.024M
YoY Change		52243.69%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	LAXXU	Prepaid Expense Paid By Related Party PrepaidExpensePaidByRelatedParty		usd
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	D8
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	c/o 6 Eu Tong Sen Street
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	#08-13
CY2022	dei	Entity Address Country EntityAddressCountry	SG
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	059817
CY2022	dei	City Area Code CityAreaCode	65
CY2022	dei	Local Phone Number LocalPhoneNumber	6788 0388
	LAXXU	Initial Value Of Ordinary Shares Subject To Possible Redemption InitialValueOfOrdinarySharesSubjectToPossibleRedemption		usd
	LAXXU	Subsequent Measurement Of Ordinary Shares Subject To Possible Redemption SubsequentMeasurementOfOrdinarySharesSubjectToPossibleRedemption		usd
	LAXXU	Deferred Underwriting Commission DeferredUnderwritingCommission		usd
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities		usd
	LAXXU	Principal Deposited In Trust Account PrincipalDepositedInTrustAccount		usd
CY2022	dei	Entity Shell Company EntityShellCompany	true
CY2022Q1	dei	Entity Public Float EntityPublicFloat	84007500	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
	LAXXU	Proceeds From Underwriters Purchase Option ProceedsFromUnderwritersPurchaseOption		usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	11073500	shares
CY2022	dei	Auditor Firm AuditorFirmId	1195
	LAXXU	Payment Of Underwriting Commission PaymentOfUnderwritingCommission		usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts		usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect		usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations		usd
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations		usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations		usd
CY2022	LAXXU	Deferred Offering Costs Paid By Sponsor In Exchange For Issuance Of Ordinary Shares DeferredOfferingCostsPaidBySponsorInExchangeForIssuanceOfOrdinaryShares		usd
CY2022	LAXXU	Deferred Offering Costs Paid By Related Party DeferredOfferingCostsPaidByRelatedParty		usd
CY2022	LAXXU	Deferred Offering Costs Included In Accrued Offering Costs And Expenses DeferredOfferingCostsIncludedInAccruedOfferingCostsAndExpenses		usd
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001847846
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue		usd
CY2022Q3	us-gaap	Deferred Offering Costs DeferredOfferingCosts		usd
CY2021Q3	us-gaap	Assets Held In Trust Current AssetsHeldInTrustCurrent		usd
CY2021Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent		usd
CY2021Q3	LAXXU	Promissory Note Related Party PromissoryNoteRelatedParty		usd
CY2022Q3	LAXXU	Related Party Loans RelatedPartyLoans		usd
CY2021Q3	us-gaap	Deferred Leasing Commissions DeferredLeasingCommissions		usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent		usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue		usd
CY2021Q3	us-gaap	Common Stock Value CommonStockValue		usd
CY2021	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2022	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital		usd
	LAXXU	Dividends On Marketable Securities Held In Trust DividendsOnMarketableSecuritiesHeldInTrust		usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense		usd
	LAXXU	Basic And Diluted Weighted Average Redeemable Ordinary Shares Outstanding Basic And Diluted BasicAndDilutedWeightedAverageRedeemableOrdinarySharesOutstandingBasicAndDiluted		shares
	LAXXU	Basic And Diluted Net Income Per Redeemable Ordinary Share BasicAndDilutedNetIncomePerRedeemableOrdinaryShare
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity		usd
CY2022	LAXXU	Formation And Operating Costs Paid By Related Party FormationAndOperatingCostsPaidByRelatedParty		usd
	LAXXU	Dividends Earned On Cash And Marketable Securities Held In Trust Account DividendsEarnedOnCashAndMarketableSecuritiesHeldInTrustAccount		usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense		usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities		usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties		usd
CY2022	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-07-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--07-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-40462
CY2022	dei	Entity Registrant Name EntityRegistrantName	8i ACQUISITION 2 CORP.
CY2022	dei	Auditor Name AuditorName	UHY LLP
CY2022	dei	Auditor Location AuditorLocation	New York, New York
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	193546	usd
CY2022Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	109143	usd
CY2021Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	181000	usd
CY2021Q3	us-gaap	Deferred Offering Costs DeferredOfferingCosts	247920	usd
CY2022Q3	us-gaap	Assets Held In Trust Current AssetsHeldInTrustCurrent	86472912	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	86775601	usd
CY2021Q3	us-gaap	Assets Current AssetsCurrent	428920	usd
CY2022Q3	us-gaap	Assets Assets	86775601	usd
CY2021Q3	us-gaap	Assets Assets	428920	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	824410	usd
CY2021Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3640	usd
CY2022Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	86894	usd
CY2022Q3	LAXXU	Promissory Note Related Party PromissoryNoteRelatedParty	800000	usd
CY2021Q3	LAXXU	Related Party Loans RelatedPartyLoans	396157	usd
CY2022Q3	us-gaap	Deferred Leasing Commissions DeferredLeasingCommissions	3018750	usd
CY2022Q3	us-gaap	Liabilities Liabilities	4730054	usd
CY2021Q3	us-gaap	Liabilities Liabilities	399797	usd
CY2022Q3	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	8225000	shares
CY2022Q3	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	10.03
CY2022Q3	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	400000	shares
CY2022Q3	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	8.27
CY2022Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	85769097	usd
CY2021Q3	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2022Q3	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2448500	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2448500	shares
CY2022Q3	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares	400000	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2156250	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2156250	shares
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	37500	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3723550	usd
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8377	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-3723550	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	29123	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	86775601	usd
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	428920	usd
CY2022	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1985750	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	8377	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-1985750	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-8377	usd
CY2022	LAXXU	Dividends On Marketable Securities Held In Trust DividendsOnMarketableSecuritiesHeldInTrust	222912	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	222912	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-1762838	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8377	usd
CY2022	LAXXU	Basic And Diluted Weighted Average Redeemable Ordinary Shares Outstanding Basic And Diluted BasicAndDilutedWeightedAverageRedeemableOrdinarySharesOutstandingBasicAndDiluted	5883904	shares
CY2022	LAXXU	Basic And Diluted Net Income Per Redeemable Ordinary Share BasicAndDilutedNetIncomePerRedeemableOrdinaryShare	0.50
CY2022	LAXXU	Weighted Average Shares Outstanding Of Nonredeemable Ordinary Shares WeightedAverageSharesOutstandingOfNonredeemableOrdinaryShares	2355621	shares
	LAXXU	Weighted Average Shares Outstanding Of Nonredeemable Ordinary Shares WeightedAverageSharesOutstandingOfNonredeemableOrdinaryShares	1875000	shares
CY2022	LAXXU	Basic And Diluted Net Loss Per Share Nonredeemable Ordinary Shares BasicAndDilutedNetLossPerShareNonredeemableOrdinaryShares	-2.00
	LAXXU	Basic And Diluted Net Loss Per Share Nonredeemable Ordinary Shares BasicAndDilutedNetLossPerShareNonredeemableOrdinaryShares	-0.00
	LAXXU	Issuance Of Ordinary Shares To Initial Shareholder Upon Formation IssuanceOfOrdinarySharesToInitialShareholderUponFormation	1	usd
	LAXXU	Issuance Of Ordinary Shares To Initial Shareholder IssuanceOfOrdinarySharesToInitialShareholder	37499	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8377	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	29123	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	86250000	usd
CY2022	us-gaap	Stockholders Equity Other StockholdersEquityOther	2922500	usd
CY2022	us-gaap	Stock Option Down Round Feature Increase Decrease In Equity Amount1 StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount1	100	usd
CY2022	LAXXU	Underwriters Commission UnderwritersCommission	-1725000	usd
CY2022	LAXXU	Deferred Underwriter Commission DeferredUnderwriterCommission	-3018750	usd
CY2022	LAXXU	Other Offering Expenses OtherOfferingExpenses	-649588	usd
CY2022	LAXXU	Ordinary Shares Subject To Redemption OrdinarySharesSubjectToRedemption	-71074007	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments	-14695090	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-1762838	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-3723550	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-1762838	usd
	us-gaap	Net Income Loss NetIncomeLoss	-8377	usd
	LAXXU	Formation And Operating Costs Paid By Related Party FormationAndOperatingCostsPaidByRelatedParty	-8377	usd
CY2022	LAXXU	Dividends Earned On Cash And Marketable Securities Held In Trust Account DividendsEarnedOnCashAndMarketableSecuritiesHeldInTrustAccount	222912	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-71857	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	820770	usd
CY2022	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	86894	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1006229	usd
CY2022	LAXXU	Principal Deposited In Trust Account PrincipalDepositedInTrustAccount	86250000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-86250000	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	86250000	usd
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	2922500	usd
CY2022	LAXXU	Proceeds From Underwriters Purchase Option ProceedsFromUnderwritersPurchaseOption	100	usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	800000	usd
CY2022	LAXXU	Payment Of Underwriting Commission PaymentOfUnderwritingCommission	-1725000	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	396157	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	401668	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	87449775	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	193546	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	193546	usd
	LAXXU	Deferred Offering Costs Paid By Sponsor In Exchange For Issuance Of Ordinary Shares DeferredOfferingCostsPaidBySponsorInExchangeForIssuanceOfOrdinaryShares	37500	usd
	LAXXU	Deferred Offering Costs Paid By Related Party DeferredOfferingCostsPaidByRelatedParty	206780	usd
	LAXXU	Deferred Offering Costs Included In Accrued Offering Costs And Expenses DeferredOfferingCostsIncludedInAccruedOfferingCostsAndExpenses	3640	usd
	LAXXU	Prepaid Expense Paid By Related Party PrepaidExpensePaidByRelatedParty	181000	usd
CY2022	LAXXU	Initial Value Of Ordinary Shares Subject To Possible Redemption InitialValueOfOrdinarySharesSubjectToPossibleRedemption	85546185	usd
CY2022	LAXXU	Subsequent Measurement Of Ordinary Shares Subject To Possible Redemption SubsequentMeasurementOfOrdinarySharesSubjectToPossibleRedemption	222912	usd
CY2022	LAXXU	Deferred Underwriting Commission DeferredUnderwritingCommission	3018750	usd
CY2022Q3	us-gaap	Cash Cash	193546	usd
CY2022Q3	LAXXU	Working Capital WorkingCapital	1408615	usd
CY2021Q3	LAXXU	Working Capital WorkingCapital	218797	usd
CY2021Q4	us-gaap	Noninterest Expense Offering Cost NoninterestExpenseOfferingCost	5876815	usd
CY2021Q4	us-gaap	Payments For Underwriting Expense PaymentsForUnderwritingExpense	1725000	usd
CY2021Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	3018750	usd
CY2021Q4	us-gaap	Other Deferred Costs Net OtherDeferredCostsNet	649588	usd
CY2021Q4	us-gaap	Sale Of Stock Consideration Received Per Transaction SaleOfStockConsiderationReceivedPerTransaction	483477	usd
CY2021Q4	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	100	usd
CY2021Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	25000	usd
CY2021Q4	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	87114830	usd
	us-gaap	Payment For Administrative Fees PaymentForAdministrativeFees	83000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_841_eus-gaap--UseOfEstimates_zTOGlkbAdga6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zSNdwB8CTBQ5">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	193546	usd
CY2022Q3	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	86472912	usd
CY2022	LAXXU	Dividends On Marketable Securities Held In Trust DividendsOnMarketableSecuritiesHeldInTrust	222912	usd
CY2021Q4	us-gaap	Underwriting Expense Ratio UnderwritingExpenseRatio	0.020	pure
CY2021Q4	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	1725000	usd
CY2021Q4	LAXXU	Deferred Underwriting Expense Ratio DeferredUnderwritingExpenseRatio	0.035	pure
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zLVYi3pwq4fj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zjHSgYSFpuX3">Concentration of credit risk</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal depository insurance coverage of $<span id="xdx_908_eus-gaap--MalpracticeInsuranceCoverageFloor_c20210801__20220731_zSt0AhFORMh8" title="Federal depository insurance coverage">250,000</span>. As of July 31, 2022 and 2021, the Company had not experienced losses on this account.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022	us-gaap	Malpractice Insurance Coverage Floor MalpracticeInsuranceCoverageFloor	250000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-1762838	usd
CY2022	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	14695090	usd
CY2022	LAXXU	Net Loss Including Accretion Of Temporary Equity To Redemption Value NetLossIncludingAccretionOfTemporaryEquityToRedemptionValue	-16457928	usd
CY2021Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	3018750	usd
CY2021Q4	us-gaap	Other Underwriting Expense OtherUnderwritingExpense	225000	usd
CY2022	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	500000	usd
CY2022Q3	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2021Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1437500	shares
CY2022Q3	us-gaap	Temporary Equity Aggregate Amount Of Redemption Requirement TemporaryEquityAggregateAmountOfRedemptionRequirement	3306524	usd
CY2022	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	86250000	usd
CY2022	LAXXU	Proceeds Allocated To Pubic Warrants And Public Rights ProceedsAllocatedToPubicWarrantsAndPublicRights	9979125	usd
CY2022	LAXXU	Proceeds From Issuance Of Redeemable Stock ProceedsFromIssuanceOfRedeemableStock	5196868	usd
CY2022	LAXXU	Accretion Of Carrying Value To Redemption Value Deemed Dividend AccretionOfCarryingValueToRedemptionValueDeemedDividend	14695090	usd
CY2022	LAXXU	Temporary Equity Carrying Amount Subject To Possible Redemption TemporaryEquityCarryingAmountSubjectToPossibleRedemption	85769097	usd
CY2022Q3	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	3894	usd
CY2022Q3	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	3894	usd
CY2021Q4	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	396157	usd
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	25000	usd
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	11.50
CY2022	us-gaap	Class Of Warrant Or Right Reason For Issuing To Nonemployees ClassOfWarrantOrRightReasonForIssuingToNonemployees	No fractional warrant will be issued and only whole warrants will trade. The Company may redeem the warrants at a price of $0.01 per warrant upon 30 days’ notice, only in the event that the last sale price of the ordinary shares is at least $16.50 per share for any 20 trading days within a 30-trading day period ending on the third day prior to the date on which notice of redemption is given, provided there is an effective registration statement and current prospectus in effect with respect to the ordinary shares underlying such warrants during the 30 day redemption period. If a registration statement is not effective within 60 days following the consummation of a business combination, warrant holders may, until such time as there is an effective registration statement and during any period when the Company shall have failed to maintain an effective registration statement, exercise warrants on a cashless basis pursuant to an available exemption from registration under the Securities Act.
CY2022	LAXXU	Warrants Redemption Price WarrantsRedemptionPrice	0.01
CY2022Q3	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	86472912	usd
CY2022Q3	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	86472912	usd

Files In Submission

Name	View Source	Status
0001493152-22-024263-index-headers.html	Edgar Link	pending
0001493152-22-024263-index.html	Edgar Link	pending
0001493152-22-024263.txt	Edgar Link	pending
0001493152-22-024263-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
laxxu-20220731.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
laxxu-20220731_lab.xml	Edgar Link	unprocessable
laxxu-20220731_cal.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
laxxu-20220731_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
laxxu-20220731_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EUDA
EUDA Health Holdings Ltd Stock $euda

2022 Q3 Form 10-K Financial Statement

#000149315222024263 Filed on August 29, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EUDA EUDA Health Holdings Ltd Stock $euda

2022 Q3 Form 10-K Financial Statement

#000149315222024263 Filed on August 29, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EUDA
EUDA Health Holdings Ltd Stock $euda